Frontiers in Cardiovascular Medicine (Dec 2021)
Positive Association Between Serum Alkaline Phosphatase and First Stroke in Hypertensive Adults
- Yuanyuan Zhang,
- Yuanyuan Zhang,
- Yuanyuan Zhang,
- Yuanyuan Zhang,
- Yuanyuan Zhang,
- Yuanyuan Zhang,
- Yuanyuan Zhang,
- Huan Li,
- Huan Li,
- Huan Li,
- Huan Li,
- Huan Li,
- Huan Li,
- Huan Li,
- Di Xie,
- Di Xie,
- Di Xie,
- Di Xie,
- Di Xie,
- Di Xie,
- Di Xie,
- Jianping Li,
- Yan Zhang,
- Binyan Wang,
- Chengzhang Liu,
- Yun Song,
- Xiaobin Wang,
- Yong Huo,
- Fan Fan Hou,
- Fan Fan Hou,
- Fan Fan Hou,
- Fan Fan Hou,
- Fan Fan Hou,
- Fan Fan Hou,
- Fan Fan Hou,
- Xiping Xu,
- Xiping Xu,
- Xiping Xu,
- Xiping Xu,
- Xiping Xu,
- Xiping Xu,
- Xiping Xu,
- Xianhui Qin,
- Xianhui Qin,
- Xianhui Qin,
- Xianhui Qin,
- Xianhui Qin,
- Xianhui Qin,
- Xianhui Qin
Affiliations
- Yuanyuan Zhang
- Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Yuanyuan Zhang
- National Clinical Research Center for Kidney Disease, Guangzhou, China
- Yuanyuan Zhang
- State Key Laboratory of Organ Failure Research, Guangzhou, China
- Yuanyuan Zhang
- Guangdong Provincial Institute of Nephrology, Guangzhou, China
- Yuanyuan Zhang
- Guangdong Provincial Clinical Research Center for Kidney Disease, Guangzhou, China
- Yuanyuan Zhang
- Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, China
- Yuanyuan Zhang
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China
- Huan Li
- Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Huan Li
- National Clinical Research Center for Kidney Disease, Guangzhou, China
- Huan Li
- State Key Laboratory of Organ Failure Research, Guangzhou, China
- Huan Li
- Guangdong Provincial Institute of Nephrology, Guangzhou, China
- Huan Li
- Guangdong Provincial Clinical Research Center for Kidney Disease, Guangzhou, China
- Huan Li
- Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, China
- Huan Li
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China
- Di Xie
- Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Di Xie
- National Clinical Research Center for Kidney Disease, Guangzhou, China
- Di Xie
- State Key Laboratory of Organ Failure Research, Guangzhou, China
- Di Xie
- Guangdong Provincial Institute of Nephrology, Guangzhou, China
- Di Xie
- Guangdong Provincial Clinical Research Center for Kidney Disease, Guangzhou, China
- Di Xie
- Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, China
- Di Xie
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China
- Jianping Li
- Department of Cardiology, Peking University First Hospital, Beijing, China
- Yan Zhang
- Department of Cardiology, Peking University First Hospital, Beijing, China
- Binyan Wang
- Institute of Biomedicine, Anhui Medical University, Hefei, China
- Chengzhang Liu
- Institute of Biomedicine, Anhui Medical University, Hefei, China
- Yun Song
- 0Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China
- Xiaobin Wang
- 1Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States
- Yong Huo
- Department of Cardiology, Peking University First Hospital, Beijing, China
- Fan Fan Hou
- Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Fan Fan Hou
- National Clinical Research Center for Kidney Disease, Guangzhou, China
- Fan Fan Hou
- State Key Laboratory of Organ Failure Research, Guangzhou, China
- Fan Fan Hou
- Guangdong Provincial Institute of Nephrology, Guangzhou, China
- Fan Fan Hou
- Guangdong Provincial Clinical Research Center for Kidney Disease, Guangzhou, China
- Fan Fan Hou
- Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, China
- Fan Fan Hou
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China
- Xiping Xu
- Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Xiping Xu
- National Clinical Research Center for Kidney Disease, Guangzhou, China
- Xiping Xu
- State Key Laboratory of Organ Failure Research, Guangzhou, China
- Xiping Xu
- Guangdong Provincial Institute of Nephrology, Guangzhou, China
- Xiping Xu
- Guangdong Provincial Clinical Research Center for Kidney Disease, Guangzhou, China
- Xiping Xu
- Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, China
- Xiping Xu
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China
- Xianhui Qin
- Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Xianhui Qin
- National Clinical Research Center for Kidney Disease, Guangzhou, China
- Xianhui Qin
- State Key Laboratory of Organ Failure Research, Guangzhou, China
- Xianhui Qin
- Guangdong Provincial Institute of Nephrology, Guangzhou, China
- Xianhui Qin
- Guangdong Provincial Clinical Research Center for Kidney Disease, Guangzhou, China
- Xianhui Qin
- Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, China
- Xianhui Qin
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China
- DOI
- https://doi.org/10.3389/fcvm.2021.749196
- Journal volume & issue
-
Vol. 8
Abstract
The relation of alkaline phosphatase (ALP) with stroke risk remains uncertain. We aimed to examine the association between serum ALP and the risk of first stroke, and explore the possible effect modifiers in the association, among adults with hypertension. A total of 19,747 participants with baseline ALP measurements and without liver disease at baseline from the China Stroke Primary Prevention Trial (CSPPT) were included. The primary outcome was a first stroke. Over a median follow-up of 4.5 years, there was a positive association between serum ALP levels and the risk of first stroke (per SD increment, adjusted HR, 1.10; 95%CI: 1.01, 1.20). When serum ALP was evaluated as quartiles, a significantly higher risk of first stroke was observed in those in quartile 2–4 (ALP ≥79 IU/L; adjusted HR, 1.38; 95% CI: 1.11, 1.71), compared with participants in quartile 1 (ALP <79 IU/L). Similar results were found for first ischemic or hemorrhagic stroke. Similar findings were also found in those with a normal range of baseline ALP levels (20–140 IU/L) (per SD increment, adjusted HR, 1.15; 95%CI: 1.05, 1.27). None of the variables, including sex, age, body mass index, smoking, alcohol drinking, blood pressure, total cholesterol, fasting glucose levels at baseline, and blood pressure levels during the treatment period, significantly modified the association. In summary, our study suggests that higher serum ALP levels, even in normal range, were significantly related to higher risk of first stroke among Chinese hypertensive adults.
Keywords